Breaking News

Clearside reports BCVA gain in phase 1/2 trial of suprachoroidal injection of triamcinolone acetonide

Patients with noninfectious uveitis experienced an improvement in best corrected visual acuity in a phase 1/2 clinical trial involving a suprachoroidal injection of triamcinolone acetonide, Clearside Biomedical reported in a press release.

The trial included eight patients who received a single suprachoroidal injection of triamcinolone acetonide with Clearside's proprietary microinjector.

Mean improvement in BCVA was more than two lines on an ETDRS eye chart at week 12 and close to three lines at week 26, the release said. At weeks 12 and 26, mean reduction in retinal thickness was more than 100 µm from the respective baseline levels.

None of the patients experienced a significant increase in IOP after the injection of triamcinolone acetonide, and no IOP-lowering medications were needed, the release said. The injection was generally safe and well tolerated.

Patients with noninfectious uveitis experienced an improvement in best corrected visual acuity in a phase 1/2 clinical trial involving a suprachoroidal injection of triamcinolone acetonide, Clearside Biomedical reported in a press release.

The trial included eight patients who received a single suprachoroidal injection of triamcinolone acetonide with Clearside's proprietary microinjector.

Mean improvement in BCVA was more than two lines on an ETDRS eye chart at week 12 and close to three lines at week 26, the release said. At weeks 12 and 26, mean reduction in retinal thickness was more than 100 µm from the respective baseline levels.

None of the patients experienced a significant increase in IOP after the injection of triamcinolone acetonide, and no IOP-lowering medications were needed, the release said. The injection was generally safe and well tolerated.